Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines
The FASEB Journal · 2023
DOI: 10.1096/fj.202201217rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Lihong Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Mo…. Hauptthemen laut MEDLINE: CDC2-CDC28 Kinases, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Cyclin‐dependent kinases 2 (CDK2) is a serine/threonine‐protein kinase, which plays a key role in the regulation of cell cycle and is related to the occurrence and development of melanoma. In this study, we identified potent inhibitors for CDK2 by combining a multistage virtual screening strategy with bioassay validations. The biochemical activity of compounds was validated with ADP‐Glo™ Kinase assay in vitro, and the results indicated that the biochemical activity of compound 1 (C1) was better than other selected compounds. Cell viability assay showed that the minimum inhibition concentration of C1 for CDK2 was lower than 4 μM. Further functional test results showed that C1 exerted significant antiproliferative, pro‐apoptosis, and anti‐migration activity in melanoma cell lines (A375 cells, WM35 cells, and A875 cells). Our findings suggested that the C1, virtually screened from compound libraries, as the novel inhibitor of CDK2, may be further developed as an effective therapeutic agent in the treatment of melanoma lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Ton…
- Platform of Pharmaceutical Intelligence, Tianjin International Joint Academy of Biomedicine, Tianjin, 300457, China.
- Biodesign Center, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin, 300308, China.
Zitieren
APA
Yang, L., Wang, M., Li, B., Xu, S., & Lin, J. (2023). Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines. The FASEB Journal. https://doi.org/10.1096/fj.202201217rr
Vancouver
Yang L, Wang M, Li B, Xu S, Lin J. Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines. The FASEB Journal. 2023. doi:10.1096/fj.202201217rr
BibTeX
@article{Yang2023,
author = {Yang, Lihong and Wang, Mukuo and Li, Beibei and Xu, Shangqin and Lin, Jianping},
title = {Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201217rr}
}
EUVIMED